Robert A. Goodnow Jr, PhD   –   Independent Drug Discovery Innovation Consultant

My Background
I have broad experience in drug discovery that can move forward your project.  I am a research and development (R&D) leader with deep expertise in most drug discovery modalities, including small molecules, ADCs, oligonucleotides, peptides, passive and targeted LNPs, RNA modulation, and anti-body targeting.  I have developed this expertise through over 30 years in pharma, biotech, CRO, and VC-based research organizations, working on over 100 projects. I have held multiple scientific leadership positions at  Roche, AstraZeneca, Takeda, Stoke Therapeutics, and Pharmaron / PharmaPier managing teams as large as 150 internal FTEs.  I am an inventor or co-inventor on >40 patent applications, including more than 20 issued patents.  I have authored or co-authored >60 scientific manuscripts.

What I do as a consultant:
With deep understanding of drug discovery processes from target identification and project conception through Phase 1, I am excited to bring your innovation to market.  Having worked with search and evaluation teams as well as business development colleagues, I can help you navigate effective partnership discussions with pharma and biotech.  I am passionate about drug discovery sciences in general, but I excel at evaluating each project’s unique merits and determining the appropriate strategy and tactics to advance your project.

I will help you avoid the dead ends that will kill your project and deplete your resources.  I will also help you navigate the consultant and CRO market place to get meaningful results.  My service are dynamic and customized to your needs.  I am excited to work with early start ups as well as well more established companies. 

Areas of expertise:
– Oligonucleotide therapeutics and related delivery systems such as targeted lipid nanoparticles (LNPs)
– Hit and lead identification technologies, including DNA-encoded chemistry (DEL)
– Medicinal chemistry (particularly hit generation), peptides, biologics and ADCs
– Laboratory automation technologies, including sample management solutions
– Early development project management and scientific writing
– CRO, collaboration, and alliance management
– Due diligence, technology evaluation, and tech transfer
– Therapeutic expertise in inflammation, metabolic diseases, oncology, and neuroscience
– Languages: English, Japanese, Chinese, French, and Spanish

References, case histories and other information are available upon request.